Combination of Clozapine and Amisulpride in Treatment-Resistant Schizophrenia - Case Reports and Review of the Literature

Pharmacopsychiatry

Volumn 37, Issue 1, 2004, Pages 26-31

  Zink, Mathias ^a   Knopf, Udo ^a   Henn, Fritz A ^a   Thome, Johannes ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE;

AKATHISIA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; EPILEPTIC STATE; HUMAN; HYPERSALIVATION; INFORMATION PROCESSING; LEUKOPENIA; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL RECORD; MONOTHERAPY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; UTILIZATION REVIEW; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 1242292411     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815471     Document Type: Review

References (55)

1. Adler G, Grieshaber S, Faude V, Thebaldi B, Dressing H. Clozapine in patients with chronic schizophrenia: Serum level, EEG and memory performance. Pharmacopsychiatry 2002; 35: 190-194
2. Barnes TR, McEvedy CJ, Nelson HE. Management of treatment resistant schizophrenia unresponsive to clozapine. Br J Psychiat - Suppl 1996; 31: 31-40
3. Bennett MR. Monoaminergic synapses and schizophrenia: 45 years of neuroleptics. J Psychopharmacol 1998; 12(3): 289-304
4. Bleuler E. Handbuch der Psychiatrie. Spezieller Teil. 4. Abteilung. 1911: Dementia praecox oder die Gruppe der Schizophrenien
5. Bottlender R, Jager M, Hofschuster E, Dobmeier P, Moller HJ. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry 2002; 35(3): 119-121
6. Buchanan RW. Clozapine: efficacy and safety. Schizophr Bull 1995; 21(4): 579-591
7. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000; 38(5): 393-414
8. Chong SA, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000; 26(2): 421-440
9. Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry - Revue Canadienne de Psychiatrie 2001; 46(1): 86-87
10. Cooke C, de Leon J. Adding other antipsychotics to clozapine. J Clin Psychiat 1999; 60(10): 710
11. Croissant B, Hermann D, Olbrich R. Saving potential of clozapine due to combination with amisulpride. Psychopharmakotherapie 2002; 8(3): 128-130
12. de Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiat 2001; 62(2): 129-130
13. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study. Pharmacopsychiatry 1990; 23(2): 125-130
14. Deniker P. The neuroleptics: a historical survey. Acta Psychiat Scand Suppl 1990; 358: 83-87
15. Duval AM, Goldman D. The new drugs (chlorpromazine & reserpine): administrative aspects. 1956. Psychiat Serv 2000; 51(3): 327-331
16. Freudenreich O, Goff DC Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiat Scand 2002; 106: 323-330
17. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiat 1997; 42(6): 522-523
18. Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harv Rev Psychiat 1995; 3(1): 1-9
19. Grohmann R, Koch R, Schmidt LG. Extrapyramidal symptoms in neuroleptic recipients. Agents Actions - Suppl 1990; 29: 71-82
20. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiat 1998; 10(3): 113-115
21. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiat 1999; 60 Suppl 23: 14-19
22. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiat 1996; 57(9): 395-397
23. Horacek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry 2000; 33 Suppl 1: 34-42
24. Koshino Y. Algorithm for treatment-refractory schizophrenia. Psychiat Clin Neurosci 1999; 53 Suppl: S9S13
25. Kraepelin E. Dementia precox and paraphrenia. 8. Edinburgh: E. and S. Livingstone, 1919
26. Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T et al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001; 44(1): 41-46
27. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: A meta-Analysis of randomized controlled trials. Am J Psychiat 2002; 159: 180-190
28. Mann K, Bartels M, Bauer H, Gaertner HJ. Amisulpride - an open clinical study of a new benzamide in schizophrenic patients. Pharmacopsychiatry 1984; 17(4): 111-115
29. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33 Suppl 1: 14-33
30. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiat 1994; 55 Suppl B: 7-52
31. Meyer JM, Simpson GM. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiat Serv 1997; 48(9): 1137-1139
32. Miller DD. Review and management of clozapine side effects. J Clin Psychiat 2000; 61 Suppl 8: 14-17; discussion 18-17; discussion 18-19
33. Moeller HJ. Amisulpride: a review of its efficacy in schizophrenia. Acta Psychiat Scand Suppl 2000; 400: 17-22
34. Moore NA. Behavioural pharmacology of the new generation of anti-psychotic agents. Br J Psychiat Suppl 1999; 38: 5-11
35. Pantelis C, Barnes TR. Drug strategies and treatment-resistant schizophrenia. Aust N Z J Psychiat 1996; 30(1): 20-37
36. Pantelis C, Barnes TR. Drug strategies and treatment-resistant schizophrenia. Aust N Z J Psychiat 1996; 30(1): 20-37
37. Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999; 9(4): 301-309
38. Raskin S, Katz G, Zislin Z, Knobler HY, Durst R. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiat Scand 2000; 101(4): 334-336
39. Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short-and long-term use. Acta Psychiat Scand Suppl 2000; 400: 23-27
40. Rein W, Turjanski S. Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 1997; 12 Suppl 2: S19-27
41. Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997; 12 Suppl 2: S29-36
42. Sethi KD. Movement disorders induced by dopamine blocking agents. Semin Neurol 2001; 21(1): 59-68
43. Shen WW. A history of antipsychotic drug development. Compr Psychiat 1999; 40(6): 407-414
44. Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiat 1997; 171: 569-573
45. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiat 1999; 60(7): 425-426
46. Stahl SM. Antipsychotic polypharmacy: evidence based or eminence based? Acta Psychiat Scand 2002; 106: 321-322
47. Stahl SM. Antipsychotic polypharmacy: squandering precious recources? J Clin Psychiat 2002; 63(2): 93-94
48. Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine. A review. Br J Psychiat Suppl 1999; (38): 52-58
49. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiat 1997; 42(2): 138-143
50. Stubbs JH, Haw CM, Staley CJ, Mountjoy CQ. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiat Scand 2000; 102(5): 390-393; discussion 393-393; discussion 393-394
51. Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001; 48(1): 155-158
52. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiat 2001; 62 Suppl 21: 7-10
53. Wirshing DA, Wirsshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiat 1999; 60: 358-363
54. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24: 381-390
55. Young CR, Longhurst JG, Bowers MB Jr, Mazure CM. The expanding indications for clozapine. Exp Clin Psychopharmacol 1997; 5(3): 216-234